{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most prevalent known cause of autosomal dominant Parkinson's disease (PD). The LRRK2 gene encodes a Roco protein featuring a ROC GTPase and a kinase domain linked by the C-terminal of ROC (COR) domain.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism relevant to the LRRK2 gene and its role in Parkinson's disease, including its GTPase and kinase activity."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study explored the effects of the Y1699C pathogenic LRRK2 mutation in the COR domain on GTPase activity and interactions within the catalytic core of LRRK2 using various assays including GTPase assays, GST pulldowns, and yeast two-hybrid assays.",
          "judgment": "Yes",
          "reasoning": "These assays effectively model or reflect the disease pathogenesis/mechanism defined in Step 1 by evaluating the functional impact of the Y1699C mutation on LRRK2's GTPase activity and protein-protein interactions, which are central to the molecular pathogenesis of PD associated with LRRK2 mutations.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "judgment": "Yes",
          "reasoning": "The paper includes appropriate positive and negative controls, replicates, and previously validated assays to evaluate the effects of the Y1699C mutation on LRRK2 function.",
          "next_step_or_outcome": "Proceed to Step 4"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step_name": "Sub-step 4a: Statistical Analyses",
          "extracted_paper_info": "Statistical significance was determined using a Student's t-test (two-tailed) for various assays, including GTPase activity assays, pulldown assays, and yeast two-hybrid assays.",
          "judgment": "Yes",
          "reasoning": "The paper provides sufficient statistical analyses to estimate the effect of the Y1699C mutation on LRRK2 function.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "sub_step_name": "Sub-step 4c: Correlate OddsPath",
          "extracted_paper_info": "The study found that the Y1699C mutation reduces LRRK2 GTPase activity, weakens ROC-COR dimerization, and strengthens the intra-molecular ROC:COR interaction, leading to a decrease in LRRK2 GTPase activity.",
          "judgment": "Yes",
          "reasoning": "Based on the functional assays and statistical analyses, the evidence supports the pathogenicity of the Y1699C variant.",
          "next_step_or_outcome": "Determine evidence strength"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_very_strong"
      },
      "overall_conclusion": "The Y1699C pathogenic mutation in LRRK2 reduces GTPase activity, weakens ROC-COR dimerization, and strengthens the intra-molecular ROC:COR interaction, leading to a decrease in LRRK2 GTPase activity. The functional evidence from various assays, along with statistical support, strongly indicates that the Y1699C variant is pathogenic."
    }
  ]
}